MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202611009866 A) filed by Swami Vivekananda Subharti University, Meerut, Uttar Pradesh, on Jan. 30, for 'a dual-trigger, nanostructured thermo-responsive ophthalmic droplet system for extended ocular retention and controlled drug release.'
Inventor(s) include Dr. Charu Saxena.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention relates to a dual-trigger, nanostructured thermo-responsive ophthalmic droplet system designed to enhance ocular drug delivery and therapeutic efficacy. The system comprises drug-loaded nanocarriers uniformly embedded within a precisely tuned thermo- sensitive polymeric matrix. The formulation remains as a low-viscosity, free-flowing liquid at room temperature, enabling easy ocular instillation, and undergoes a reversible sol-to-gel transition strictly at ocular surface temperature ranging from 32 C to 35 C. Upon gelation, a transparent in-situ gel depot is formed on the ocular surface, significantly reducing precorneal drug loss caused by tear turnover and nasolacrimal drainage. The nanocarrier-embedded gel provides extended ocular residence time of at least six hours and enables controlled, sustained drug release with substantially zero initial burst release"
Disclaimer: Curated by HT Syndication.
